Clinical Trial Site

Norfolk, Virginia 23507

4 studies enrolling now · 14 studies all time

What they study most

Breast Cancer, ER Positive Breast Cancer, Familial Amyloidotic Cardiomyopathy (FAC), HER2 Negative Breast Carcinoma, Hearing Loss, Sensorineural, Hepatitis C, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Iron Deficiency Anemia, Lichen Planopilaris, Locally Advanced Breast Cancer

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris — Recruiting now
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants — Completed
• A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) — Completed
• FX-322 in Adults With Acquired Sensorineural Hearing Loss — Completed
• FX-322 in Adults With Age-Related Sensorineural Hearing Loss — Completed
• A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia — Completed
• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia — Completed
• FX-322 in Adults With Severe Sensorineural Hearing Loss — Completed
• DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis — Completed